Search

Sponsor opportunities

The European Hematology Association (EHA) invites you to support the EHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and differences of myeloid neoplasms.

Read more

Sponsor opportunities

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies with the practical tools to translate emerging data into the best therapy for…

Read more

Sponsorship Opportunities

The European Hematology Association (EHA) invites you to support the EHA-SWG Scientific Meeting on Red Cell and Iron Metabolism Defects: From Basic Science to Clinical Case Application.

Read more

Scientific Meetings

The EHA-SWG Scientific Meetings have been developed as a joint effort of the EHA Specialized Working Groups (SWGs) and EHA to intensify the beneficial collaboration.

Read more

Call for interest — new La Cantera event

The call for interest is closed at 23:59 on November 30, 2024. In 2025, EHA will provide funding for a new La Cantera coaching event.

Read more

Sponsor opportunities

The European Hematology Association (EHA) invites you to support the EHA Research Conference 2025, titled "Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis" 

This meeting enables the industry to network with delegates, demonstrate their products and present their latest material…

Read more

Lymphoma, multiple myeloma and marrow failure syndromes better understood during Sri Lanka tutorial

Hematologists from Sri Lanka and surrounding countries learned how to best care for patients with lymphoma, multiple myeloma and bone marrow failure syndromes and stem cell transplantation during the joint Tutorial organized by EHA with the Sri Lanka College of…

Read more

SWG Education Activities

Session at EHA2023The EHA2023 Congress was held in Frankfurt in June 2023. During the event, we held a session with the EHA Adolescent and Young Adult (AYA) Taskforce on the treatment of AYA patients with acute lymphoblastic leukaemia (ALL).

Read more